Rapid Development of an Amorphous Solid Dispersion (ASD) – Nifedipine (NIF)

Publisher: Triclinic Labs, Inc

Access this content

Your content has been opened.

Please verify you are a human before downloading this content.

Rapid Development of an Amorphous Solid Dispersion (ASD) – Nifedipine (NIF) has been emailed to . Entered the wrong email?

Don't see the content in your inbox?
Make sure to check your spam and other messages folders.

Can't get to your email right now?

To complete your registration and access this content, enter the sign-in code sent to your email.

Please enter a valid verification code.

Code sent to:

Also, remember to check in your spam, promotions, and other folders.


Register to access this content


By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.

Rapid Development of an Amorphous Solid Dispersion (ASD) – Nifedipine (NIF)

Amorphous solid dispersions (ASD) have long been used to increase the solubility and bio-availability of poorly-soluble compounds. A considerable amount of research has been car-ried out and has generated useful techniques in the area of ASD development. Surprisingly, the number of examples with successful application of the available techniques has been meager. Herein, a case study with nifedipine is presented where ASD candidates were rap-idly determined within 2-3 weeks by utilizing a compilation of these techniques. Keywords: Amorphous Solid Dispersion (ASD), Spray Drying, Crystallization, Solubility, Sta-bility, Dissolution